Novel actions of bisphosphonates in bone: Preservation of osteoblast and osteocyte viability

被引:198
作者
Bellido, Teresita [1 ,2 ]
Plotkin, Lilian I. [1 ]
机构
[1] Indiana Univ Sch Med, Dept Anat & Cell Biol, Indianapolis, IN 46202 USA
[2] Indiana Univ Sch Med, Dept Internal Med, Div Endocrinol, Indianapolis, IN 46202 USA
基金
美国国家卫生研究院;
关键词
Bisphosphonate; Osteoblast; Osteocyte; Apoptosis; ERKs; Connexin43; NITROGEN-CONTAINING BISPHOSPHONATE; ZOLEDRONIC ACID; IN-VITRO; OSTEOGENIC DIFFERENTIATION; GAP-JUNCTIONS; CELL-LINE; APOPTOSIS; ALENDRONATE; EXPRESSION; MINERALIZATION;
D O I
10.1016/j.bone.2010.08.008
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Bisphosphonates stop bone loss by inhibiting the activity of bone-resorbing osteoclasts. However, the effect of bisphosphonates on bone mass cannot completely explain the reduction in fracture incidence observed in patients treated with these agents. Recent research efforts provided an explanation to this dichotomy by demonstrating that part of the beneficial effect of bisphosphonates on the skeleton is due to prevention of osteoblast and osteocyte apoptosis. Work of our group, independently confirmed by other investigators, demonstrated that bisphosphonates are able to prevent osteoblast and osteocyte apoptosis in vitro and in vivo. This prosurvival effect is strictly dependent on the expression of connexin (Cx) 43, as demonstrated in vitro using cells lacking Cx43 or expressing dominant-negative mutants of the protein as well as in vivo using Cx43 osteoblast/osteocyte-specific conditional knock-out mice. Remarkably, this Cx43-dependent survival effect of bisphosphonates is independent of gap junctions and results from opening of Cx43 hemichannels. Hemichannel opening leads to activation of the kinases Src and extracellular signal-regulated kinases (ERKs), followed by phosphorylation of the ERK cytoplasmic target p90(RSK) kinase and its substrates BAD and C/EBP beta, resulting in inhibition of apoptosis. The antiapoptotic effect of bisphosphonates is separate from the effect of the drugs on osteoclasts, as analogs that lack antiresorptive activity are still able to inhibit osteoblast and osteocyte apoptosis in vitro. Furthermore, a bisphosphonate analog that does not inhibit osteoclast activity prevented osteoblast and osteocyte apoptosis and the loss of bone mass and strength induced by glucocorticoids in mice. Preservation of the bone-forming function of mature osteoblasts and maintenance of the osteocytic network, in combination with lack anticatabolic actions, open new therapeutic possibilities for bisphosphonates in the treatment of osteopenic conditions in which decreased bone resorption is not desired. This article is part of a Special Issue entitled Bisphosphonates. (C) 2010 Elsevier Inc. All rights reserved.
引用
收藏
页码:50 / 55
页数:6
相关论文
共 82 条
[1]   Etidronate inhibits human osteoblast apoptosis by inhibition of pro-apoptotic factor(s) produced by activated T cells [J].
Abe, Y ;
Kawakami, A ;
Nakashima, T ;
Ejima, E ;
Fujiyama, K ;
Kiriyama, T ;
Ide, A ;
Sera, N ;
Usa, T ;
Tominaga, T ;
Ashizawa, K ;
Yokoyama, N ;
Eguchi, K .
JOURNAL OF LABORATORY AND CLINICAL MEDICINE, 2000, 136 (05) :344-354
[2]   Osteocyte apoptosis is induced by weightlessness in mice and precedes osteoclast recruitment and bone loss [J].
Aguirre, JI ;
Plotkin, LI ;
Stewart, SA ;
Weinstein, RS ;
Parfitt, AM ;
Manolagas, SC ;
Bellido, T .
JOURNAL OF BONE AND MINERAL RESEARCH, 2006, 21 (04) :605-615
[3]   Skeletal involution by age-associated oxidative stress and its acceleration by loss of sex steroids [J].
Almeida, Maria ;
Han, Li ;
Martin-Millan, Marta ;
Plotkin, Lilian I. ;
Stewart, Scott A. ;
Roberson, Paula K. ;
Kousteni, Stavroula ;
O'Brien, Charles A. ;
Bellido, Teresita ;
Parfitt, A. Michael ;
Weinstein, Robert S. ;
Jilka, Robert L. ;
Manolagas, Stavros C. .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2007, 282 (37) :27285-27297
[4]   THE EFFECTS OF 2-YEAR TREATMENT WITH THE AMINOBISPHOSPHONATE ALENDRONATE ON BONE METABOLISM, BONE HISTOMORPHOMETRY, AND BONE STRENGTH IN OVARIECTOMIZED NONHUMAN-PRIMATES [J].
BALENA, R ;
TOOLAN, BC ;
SHEA, M ;
MARKATOS, A ;
MYERS, ER ;
LEE, SC ;
OPAS, EE ;
SEEDOR, JG ;
KLEIN, H ;
FRANKENFIELD, D ;
QUARTUCCIO, H ;
FIORAVANTI, C ;
CLAIR, J ;
BROWN, E ;
HAYES, WC ;
RODAN, GA .
JOURNAL OF CLINICAL INVESTIGATION, 1993, 92 (06) :2577-2586
[5]   Proteasomal degradation of Runx2 shortens parathyroid hormone-induced anti-apoptotic signaling in osteoblasts - A putative explanation for why intermittent administration is needed for bone anabolism [J].
Bellido, T ;
Ali, AA ;
Plotkin, LI ;
Fu, Q ;
Gubrij, I ;
Roberson, PK ;
Weinstein, RS ;
O'Brien, CA ;
Manolagas, SC ;
Jilka, RL .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2003, 278 (50) :50259-50272
[6]   Transcriptome and Proteome Analysis of Osteocytes Treated with Nitrogen-Containing Bisphosphonates [J].
Bivi, Nicoletta ;
Bereszczak, Jessica Z. ;
Romanello, Milena ;
Zeef, Leo A. H. ;
Delneri, Daniela ;
Quadrifoglio, Franco ;
Moro, Luigi ;
Brancia, Francesco L. ;
Tell, Gianluca .
JOURNAL OF PROTEOME RESEARCH, 2009, 8 (03) :1131-1142
[7]  
Boland R, 2003, BIOCELL, V27, P132
[8]  
BOLAND RL, 2006, J BONE MINER RES, V21
[9]  
BOYCE RW, 1995, J BONE MINER RES, V10, P211
[10]   Bone histomorphometric evaluation of pamidronate treatment in clinically manifest osteoporosis [J].
Bravenboer N. ;
Papapoulos S.E. ;
Holzmann P. ;
Hamdy N.A.T. ;
Netelenbos J.C. ;
Lips P. .
Osteoporosis International, 1999, 9 (6) :489-493